neoDisplay™ offers turnkey access to yeast display, a highly sensitive method of binder discovery leveraging fluorescence activated cell sorting (FACS) for isolation of developable, specific, and high affinity binders. neoDisplay™ comes pre-transformed with high diversity libraries for ‘plug and play’ yeast display workflows. Perform affinity maturation and humanization campaigns more rapidly by combining libraries delivered in neoDisplay™ with Neo’s 3-day sequencing and rapid variant library construction.

Neo Designed Synthetic VHH LibraryLlama VHH LibraryShips Immediately
Customer-Defined LibraryCustom Mutational SchemaSubject to Library Build Time
Customer Existing Starting Materiale.g. cDNA from immunization, pre-existing librarySubject to Library Build Time
Figure 1: Representative FACS histogram of anti-Myc signal from a displayed VHH construct.


% of population display
70% (comparable to EBY100)
Displayed Construct
N-terminal Aga2 – antibody fragment – C-terminal Myc tag
Aliquots of yeast transformed with Neo’s synthetic naive VHH library or customer library at high diversity (eg. 109)

Synthetic VHH Library

Library Size
1.3 x 109
Llama framework to enable high affinity binder discovery
CDR Diversity
  • Controlled mutagenesis library biased for CDRs to create functional binders
  • CDR3 is a mixture of 3 different lengths
  • Sequence liabilities (e.g. cysteine and methionine) are removed
Library Validation
Library diversity validated in neoDisplay by NGS; amino acid frequency matches design
Performance Validation
We performed a discovery campaign against human PD1 and discovered 33 unique binders (defined as CDR3 with at least 2 AA differences from any other sequence in set)

Using neoDisplay™ transformed with Neo’s Synthetic VHH library, we performed a discovery campaign to identify binders to PD1. We performed 2 rounds of negative selection to remove non-specific binding and 3 rounds of positive selection against PD1. We isolated 96 single cells from the positive sorting gate and identified 33 unique binder sequences (defined as at least 2 differences in CDR3 sequence).

Figure 2: Representative FACs library of negative control (black) and an anti-PD1 enriched synthetic VHH library (green). Top 0.1% of the population was sorted to enrich for highest affinity binders.


Get in touch to learn more about how neoYeast can accelerate and streamline discovery and manufacturing of new-to-nature therapeutics